{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:49:07Z","timestamp":1783424947139,"version":"3.54.6"},"reference-count":51,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR)","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"Sylvester Comprehensive Cancer Center Support Grant","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"National Institutes of Health","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"National Institutes of Health","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"National Institutes of Health","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"National Institutes of Health","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"National Institutes of Health","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"National Institutes of Health","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"National Institutes of Health","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"National Institutes of Health","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"National Institutes of Health","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"National Institutes of Health","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"Hyundai Hope on Wheels foundation","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"Sebastian Strong foundation","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"Sebastian Strong foundation","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"Sebastian Strong foundation","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"Sebastian Strong foundation","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"Sebastian Strong foundation","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"Sebastian Strong foundation","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"Sebastian Strong foundation","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"Sebastian Strong foundation","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"Sebastian Strong foundation","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"Sebastian Strong foundation","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"Woman\u2019s Cancer Association of the University of Miami","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"NIH","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"NIH","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"NIH","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"NIH","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"NIH","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"NIH","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"NIH","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"NIH","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"NIH","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"NIH","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"Florida Department of Health","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"Florida Department of Health","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"Florida Department of Health","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"Florida Department of Health","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"Florida Department of Health","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"Florida Department of Health","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"Florida Department of Health","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"Florida Department of Health","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"Florida Department of Health","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"Florida Department of Health","award":["21L01"],"award-info":[{"award-number":["21L01"]}]},{"name":"Wallace H. Coulter foundation","award":["1P30CA240139-01"],"award-info":[{"award-number":["1P30CA240139-01"]}]},{"name":"Wallace H. Coulter foundation","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]},{"name":"Wallace H. Coulter foundation","award":["R01NS092671"],"award-info":[{"award-number":["R01NS092671"]}]},{"name":"Wallace H. Coulter foundation","award":["R01MH110441"],"award-info":[{"award-number":["R01MH110441"]}]},{"name":"Wallace H. Coulter foundation","award":["DA035592"],"award-info":[{"award-number":["DA035592"]}]},{"name":"Wallace H. Coulter foundation","award":["DA035055"],"award-info":[{"award-number":["DA035055"]}]},{"name":"Wallace H. Coulter foundation","award":["AA023781"],"award-info":[{"award-number":["AA023781"]}]},{"name":"Wallace H. Coulter foundation","award":["6AZ08"],"award-info":[{"award-number":["6AZ08"]}]},{"name":"Wallace H. Coulter foundation","award":["7AZ26"],"award-info":[{"award-number":["7AZ26"]}]},{"name":"Wallace H. Coulter foundation","award":["21L01"],"award-info":[{"award-number":["21L01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The use of inhibitors of epigenetic modifiers in the treatment of acute myeloid leukemia (AML) has become increasingly appealing due to the highly epigenetic nature of the disease. We evaluated a library of 164 epigenetic compounds in a cohort of 9 heterogeneous AML patients using an ex vivo drug screen. AML blasts were isolated from bone marrow biopsies according to established protocols and treatment response to the epigenetic library was evaluated. We find that 11 histone deacetylase (HDAC) inhibitors, which act upon mechanisms of cell cycle arrest and apoptotic pathways through inhibition of zinc-dependent classes of HDACs, showed efficacy in all patient-derived samples. Other compounds, including bromodomain and extraterminal domain (BET) protein inhibitors, showed efficacy in most samples. Specifically, HDAC inhibitors are already clinically available and can be repurposed for use in AML. Results in this cohort of AML patient-derived samples reveal several epigenetic compounds with high anti-blast activity in all samples, despite the molecular diversity of the disease. These results further enforce the notion that AML is a predominantly epigenetic disease and that similar epigenetic mechanisms may underlie disease development and progression in all patients, despite differences in genetic mutations.<\/jats:p>","DOI":"10.3390\/cancers14174094","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:03:51Z","timestamp":1661375031000},"page":"4094","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients"],"prefix":"10.3390","volume":"14","author":[{"given":"Jessica L.","family":"Dennison","sequence":"first","affiliation":[{"name":"Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Al-Ali","sequence":"additional","affiliation":[{"name":"Miami Project to Cure Paralysis, Department of Neurological Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Peggy and Harold Katz Family Drug Discovery Center, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude-Henry","family":"Volmar","sequence":"additional","affiliation":[{"name":"Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Brothers","sequence":"additional","affiliation":[{"name":"Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Watts","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Wahlestedt","sequence":"additional","affiliation":[{"name":"Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Lohse","sequence":"additional","affiliation":[{"name":"Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","article-title":"Cytogenetics in Acute Leukemia","volume":"18","author":"Heerema","year":"2004","journal-title":"Blood Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2013). Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The Origin and Evolution of Mutations in Acute Myeloid Leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2011.497","article-title":"Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene","volume":"305","author":"Welch","year":"2011","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/asheducation-2011.1.36","article-title":"Impact of Genetic Features on Treatment Decisions in AML","volume":"2011","author":"Gaidzik","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fgene.2019.00133","article-title":"Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity","volume":"10","author":"Goldman","year":"2019","journal-title":"Front. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.seminoncol.2008.04.008","article-title":"Epigenetics in Acute Myeloid Leukemia","volume":"35","author":"Plass","year":"2008","journal-title":"Semin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","article-title":"CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression","volume":"168","author":"Spencer","year":"2017","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yang, X., Wong, M.P.M., and Ng, R.K. (2019). Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184576"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fcell.2020.00844","article-title":"HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia","volume":"8","author":"Spreafico","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1878-0261.12829","article-title":"Identification of RUNX1T1 as a Potential Epigenetic Modifier in Small-Cell Lung Cancer","volume":"15","author":"He","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1002\/ctm2.154","article-title":"Natural HDAC-1\/8 Inhibitor Baicalein Exerts Therapeutic Effect in CBF-AML","volume":"10","author":"Yu","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/CM9.0000000000000685","article-title":"Epigenetic Therapies in Acute Myeloid Leukemia: The Role of Hypomethylating Agents, Histone Deacetylase Inhibitors and the Combination of Hypomethylating Agents with Histone Deacetylase Inhibitors","volume":"133","author":"Xu","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1128\/MCB.01304-10","article-title":"Genomic DNA Hypomethylation by Histone Deacetylase Inhibition Implicates DNMT1 Nuclear Dynamics","volume":"31","author":"Arzenani","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise Drug Review: Azacitidine and Decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.11.008","article-title":"Ex-Vivo Sensitivity Profiling to Guide Clinical Decision Making in Acute Myeloid Leukemia: A Pilot Study","volume":"64","author":"Swords","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pleyer, L., D\u00f6hner, H., Dombret, H., Seymour, J.F., Schuh, A.C., Beach, C.L., Swern, A.S., Burgstaller, S., Stauder, R., and Girschikofsky, M. (2017). Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020415"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-014-2674-7","article-title":"A Phase I, Pharmacokinetic, and Pharmacodynamic Evaluation of the DNA Methyltransferase Inhibitor 5-Fluoro-2\u2032-Deoxycytidine, Administered with Tetrahydrouridine","volume":"75","author":"Newman","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1080\/10428194.2016.1263843","article-title":"Phase 1 Dose-Escalation Study of Oral Abexinostat for the Treatment of Patients with Relapsed\/Refractory Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia","volume":"58","author":"Vey","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","article-title":"A Phase 2 Study of Belinostat (PXD101) in Patients with Relapsed or Refractory Acute Myloid Leukemia or Patients Over 60 with Newly-Diagnosed Acute Myloid Leukemia: A California Cancer Consortium Study","volume":"55","author":"Kirschbaum","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bjh.12518","article-title":"A Randomized, Open-Label, Phase I\/II Trial to Investigate the Maximum Tolerated Dose of the Polo-like Kinase Inhibitor BI 2536 in Elderly Patients with Refractory\/Relapsed Acute Myeloid Leukaemia","volume":"163","author":"Bug","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2009-02-203547","article-title":"Early Epigenetic Changes and DNA Damage Do Not Predict Clinical Response in an Overlapping Schedule of 5-Azacytidine and Entinostat in Patients with Myeloid Malignancies","volume":"114","author":"Fandy","year":"2009","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpdd.161","article-title":"Effect of Food on the Bioavailability and Tolerability of the JAK2-Selective Inhibitor Fedratinib (SAR302503): Results from Two Phase I Studies in Healthy Volunteers","volume":"4","author":"Zhang","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1002\/cncr.30949","article-title":"Phase I Dose Escalation Multicenter Trial of Pracinostat Alone and in Combination with Azacitidine in Patients with Advanced Hematologic Malignancies","volume":"123","author":"Abaza","year":"2017","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.30533","article-title":"Phase II Randomized Double-Blinded Study of Pracinostat in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes","volume":"123","author":"Berdeja","year":"2017","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"TPS7078","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7078","article-title":"A Phase 3, Randomized Study of Pracinostat (PRAN) in Combination with Azacitidine (AZA) versus Placebo in Patients \u226518 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy (IC)","volume":"36","author":"Fong","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A Phase 1 Clinical Trial of Vorinostat in Combination with Decitabine in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1158\/1078-0432.CCR-12-2926","article-title":"A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2","volume":"19","author":"Holkova","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1200\/JCO.2011.38.3265","article-title":"Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome","volume":"30","author":"Tambaro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3324\/haematol.2011.055822","article-title":"Phase II Trial of Vorinostat and Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Older Adults with Previously Untreated Acute Myeloid Leukemia","volume":"97","author":"Walter","year":"2012","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.leukres.2018.12.011","article-title":"Combination of Sorafenib, Vorinostat and Bortezomib for the Treatment of Poor-Risk AML: Report of Two Consecutive Clinical Trials","volume":"77","author":"Sayar","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s13311-013-0226-1","article-title":"Small Molecule Inhibitors of Zinc-Dependent Histone Deacetylases","volume":"10","author":"Wagner","year":"2013","journal-title":"Neurotherapeutics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/sj.leu.2403519","article-title":"Histone Deacetylase Inhibitor NVP-LAQ824 Has Significant Activity against Myeloid Leukemia Cells in Vitro and in Vivo","volume":"18","author":"Weisberg","year":"2004","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1021\/acschembio.7b00330","article-title":"Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8","volume":"12","author":"Porter","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/jm301254q","article-title":"Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells","volume":"56","author":"Marek","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"E9135","DOI":"10.1073\/pnas.1707544114","article-title":"M344 Promotes Nonamyloidogenic Amyloid Precursor Protein Processing While Normalizing Alzheimer\u2019s Disease Genes and Improving Memory","volume":"114","author":"Volmar","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/sj.onc.1202564","article-title":"Oxamflatin Is a Novel Antitumor Compound That Inhibits Mammalian Histone Deacetylase","volume":"18","author":"Kim","year":"1999","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1158\/1078-0432.CCR-06-0429","article-title":"Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer","volume":"12","author":"Kulp","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e27785","DOI":"10.1002\/pbc.27785","article-title":"Epigenetic Drug Screen Identifies the Histone Deacetylase Inhibitor NSC3852 as a Potential Novel Drug for the Treatment of Pediatric Acute Myeloid Leukemia","volume":"66","author":"Wiggers","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute Myeloid Leukemia: A Comprehensive Review and 2016 Update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41375-018-0165-2","article-title":"Profiling of Aberrant DNA Methylation in Acute Myeloid Leukemia Reveals Subclasses of CG-Rich Regions with Epigenetic or Genetic Association","volume":"33","author":"Gebhard","year":"2019","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of Azacitidine Compared with That of Conventional Care Regimens in the Treatment of Higher-Risk Myelodysplastic Syndromes: A Randomised, Open-Label, Phase III Study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating Agents in Relapsed and Refractory AML: Outcomes and Their Predictors in a Large International Patient Cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1128\/MCB.18.12.7185","article-title":"Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO","volume":"18","author":"Gelmetti","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"San Jos\u00e9-En\u00e9riz, E., Gimenez-Camino, N., Agirre, X., and Prosper, F. (2019). HDAC Inhibitors in Acute Myeloid Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11111794"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/13543784.2017.1335711","article-title":"Investigational BET Bromodomain Protein Inhibitors in Early Stage Clinical Trials for Acute Myelogenous Leukemia (AML)","volume":"26","author":"Braun","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of Function of ASXL1 Truncating Protein in the Pathogenesis of Myeloid Malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4094\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:14:30Z","timestamp":1760141670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":51,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14174094"],"URL":"https:\/\/doi.org\/10.3390\/cancers14174094","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}